Castle Biosciences(US:CSTL) Benzinga·2025-11-05 13:02Core Insights - Castle Biosciences (NASDAQ:CSTL) experienced a rally of over 20% following a strong Q3 performance, indicating positive momentum in the stock [1] - The stock is currently in Phase 8 according to the Adhishthana Principles, having entered Phase 4 in August 2022, and is building a Cakra formation [3][5] - The stock is approaching the upper boundary of the Cakra structure, with two potential scenarios for its trajectory before transitioning into Phase 9 in January 2026 [5] Weekly Chart Analysis - The Cakra structure typically forms between Phases 4–8 and suggests bullish implications, with a breakout in Phase 9 leading to strong momentum [2] - As the stock moves through Phase 8, it has rebounded from the lower end of the Cakra and is preparing for a potential breakout [5] - Two scenarios are outlined: a rally to test the $35 level followed by a slight retracement before breaking out, or a premature breakout gaining strength in Phase 9 [5] Monthly Chart Analysis - On the monthly charts, Castle Biosciences is currently in Phase 2, which consists of the Sankhya period (consolidation or weakness) and the Buddhi period (powerful rallies) [6] - The company is in the Sankhya phase and is expected to transition into the Buddhi period in December 2025, coinciding with an anticipated increase in bullish momentum [7] Investor Outlook - For current shareholders, maintaining bullish positions is favorable, especially as momentum is expected to build once the stock surpasses the $35 mark [8] - Investors looking to enter new positions have an opportunity to accumulate shares through November, using the lower end of the Cakra as a stop-loss [8] - The overall setup indicates that Castle's base is firming up, suggesting a potential rally ahead [8]